Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-0184 in advanced solid tumors
NCT03429218Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jul 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of itacnosertib in solid tumor, sponsored by Sumitomo Pharma America. Primary endpoints: Incidence of Dose-Limiting Toxicities and Maximum Tolerated Dose at 20 months. Started Jul 2018; status: completed.
02
Drugs
itacnosertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03429218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03429218.